CJC-1295

The speaker cites FDA clinical trial data in which Tesamorelin, another GHRH analog similar in mechanism to CJC-1295, was administered continuously for 52 weeks with IGF-1 levels remaining stable throughout the entire duration. This is used as evidence that GHRH receptor agonists do not cause receptor desensitization and do not require cycling on their own. No specific dosage from the trial is mentioned.

Dr. Bachmeyer's central thesis: GH analogs cannot initiate, cause, or magnify cancer. He cites a 2004 Lancet meta-analysis (Renehan) of 22 cohort studies with 600,000+ participants showing zero association between IGF-1 levels and overall cancer incidence. A 2020 meta-analysis by Faa in Cancer journal (31 studies, 1M+ participants) also found no association. A 2012 Lancet Oncology review of 860 studies found zero evidence IGF-1 increases cancer risk in humans.

Musclein (1997) showed IGF-1 activates satellite cells — the muscle stem cells that repair damaged muscle fibers. IGF-1 also activates epidermal stem cells in skin (improving skin barrier and reducing wrinkles) and promotes neurogenesis in the brain. This represents tissue-resident stem cell activation across multiple systems.

Markx (2010) showed IGF-1 activates receptors throughout the hippocampus to promote neurogenesis (new neuron formation) throughout life. IGF-1 also increases BDNF (brain-derived neurotrophic factor) in the prefrontal cortex, promoting synaptic plasticity. Results include faster processing speed, better memory, improved executive function, and reduced neurodegenerative disease risk.

Calleo (2008) showed 4-8 pounds of lean muscle gain in 12 weeks with peptide therapy, even without training. IGF-1 drives this via the AKT/mTOR pathway: IGF-1R phosphorylates IRS-1, activates AKT (which inactivates GSK3-beta and FOXO3A — the brakes on muscle growth), and activates mTOR signaling for ribosomal biogenesis. IGF-1 also downregulates myostatin signaling.

Spallerosa (2010) proved that IGF-1 improves vascular integrity through endothelial eNOS activation. Dr. Bachmeyer argues the VEGF/angiogenesis concern is misplaced — IGF-1 promotes controlled, well-regulated vascular growth rather than erratic uncontrolled growth. Cancer cells use erratic uncontrolled growth, not controlled biologically-regulated growth.

Kelly (1986) proved IGF-1 enhances NK (natural killer) cell and T-cell function. NK cells patrol the bloodstream hunting abnormal/cancer cells and destroying them. IGF-1 also promotes T-cell differentiation in the thymus while simultaneously increasing regulatory T-cells (T-regs) to prevent autoimmunity. Stey (1994) showed IGF-1 increases NK cell proliferation and activation.

Chen (2009) in Cancer Prevention Research showed that higher IGF-1 levels were associated with lower rates of spontaneous tumor formation compared to controls. The proposed mechanism is that higher IGF-1 improves overall systemic metabolic function, mitochondrial health, and immune surveillance.

Cali (2015) in Cell Death and Differentiation showed that IGF-1 signaling enhances p53-mediated apoptosis specifically in cells with DNA damage. When a cell is damaged, IGF-1 makes it more likely to undergo programmed cell death rather than survive with mutations. This is an anti-cancer mechanism.

Ericson (2010) examined cancer risk in GH-deficient adults treated with recombinant human growth hormone. The study followed 6,000+ patients over 15+ years with profoundly elevated GH and IGF-1 levels (higher than any peptide would produce). Result: zero increased cancer incidence, actually slightly lower than age-matched controls. Additionally, a 2018 Stockholm study published in JAMA followed GH-deficient patients in Denmark and Sweden for 30+ years and found slightly lower cancer risk in treated patients.

Bartke (2004) in Aging Cell examined GH and IGF-1 across 19 lifespan studies. The consistent finding was that maintaining youthful IGF-1 signaling extends lifespan by 25% while simultaneously improving healthspan — not just living longer but living better.

IGF-1 signals senescent cells to either resume division (if conditions are favorable) or undergo apoptosis (programmed cell death). Salmon and Carn (2010) showed IGF-1 signaling promotes p53 activation, which triggers apoptosis specifically in damaged cells. This cellular cleanup is described as the primary longevity mechanism of GH analogs.

Cohen (2013) showed that IGF-1 activates telomerase, the enzyme that rebuilds telomeres. Telomere shortening with each cell division leads to cellular senescence (the Hayflick limit of ~40-60 divisions). By activating telomerase, IGF-1 from GH analogs may help maintain telomere length and delay cellular aging.

IGF-1 has direct effects on mitochondrial biogenesis through PGC-1alpha activation, which increases expression of TFAM (mitochondrial transcription factor A), increasing mitochondrial DNA copy number. It also increases antioxidant enzymes (SOD2, catalase, glutathione peroxidase). A 2015 study by Paulie showed IGF-1 signaling increases ATP production capacity in aging muscle by 50%.

The speaker distinguishes between secretagogues like CJC-1295 and exogenous growth hormone based on their relationship to the body's biological ceiling and feedback loop. Secretagogues optimize GH output within the body's natural limits while keeping the hypothalamic-pituitary feedback loop intact. Exogenous growth hormone bypasses this ceiling entirely, making it more appropriate for goals that exceed what endogenous production can achieve.

Unlike Ipamorelin, CJC-1295 acts on growth hormone releasing hormone (GHRH) receptors, which the speaker states do not experience the same desensitization problem as ghrelin receptors. CJC-1295 itself does not necessitate cycling from a receptor sensitivity standpoint. The cycling in combined protocols is attributed entirely to the ghrelin receptor agonist component.

The speaker recommends a cycling protocol of 3 months on followed by 1 month off for the CJC-1295 and Ipamorelin stack. This cycling schedule is specifically designed to allow ghrelin receptors to resensitize after the downregulation caused by continuous Ipamorelin use. No specific dosages or injection frequencies are mentioned for this protocol.

The cycling requirement for CJC-1295/Ipamorelin protocols is driven by Ipamorelin, not CJC-1295. Ipamorelin acts on ghrelin receptors, which desensitize over time as the body downregulates receptor expression on the cell surface in response to prolonged stimulation. This receptor downregulation reduces efficacy over time and necessitates cycling.

The speaker recommends stacking CJC-1295 (no DAC) with Ipamorelin as a standard protocol but advises keeping them in separate vials rather than a pre-mixed blend. While blends are generally simpler and reduce injection frequency, the stability concerns specific to this combination outweigh the convenience benefit. Users should be prepared for two separate injections.

The speaker explicitly recommends CJC-1295 without DAC as the only version worth purchasing for those seeking to preserve the natural pulsatile GH release pattern. The DAC version is compared unfavorably to exogenous growth hormone, which the speaker notes has decades of clinical data behind it for producing flat GH elevation. No-DAC CJC-1295 is preferred for maintaining physiological GH pulsatility.

The speaker warns that patients on TRT who are also prescribed an aromatase inhibitor and then offered GH peptides should question the root cause. The proper intervention is optimizing the TRT protocol to keep estrogen in normal ranges rather than crushing it with an AI and then layering on peptides to compensate. The peptides treat a symptom of poor protocol management, not a true deficiency.

Clinics prescribe testosterone, then prescribe an aromatase inhibitor for elevated estrogen (rather than optimizing the TRT protocol), which crashes estrogen and consequently collapses IGF-1 production. The clinic then sells GH-releasing peptides (CJC-1295, Ipamorelin, Tesamorelin) or IGF-1 to resolve the deficiency they created. The speaker frames this as either ignorance of the mechanism or deliberate upselling.

Starting around age 30, the pituitary gland progressively reduces growth hormone production (somatopause). By age 60, approximately 50% of GH secreting capacity is lost. This is not a disease state but a regulated decline. GH analogs aim to restore IGF-1 to youthful levels (~age 22).

Dr. Bachmeyer emphasizes that nothing else can work without growth hormone and IGF-1 functioning first. GH analogs are the foundational 'first step' in any peptide protocol. When people take random peptides without establishing GH axis function first, they miss the fundamental mechanism that enables everything else to work.

Dr. Bachmeyer presents his framework that all chronic disease cascades from three biological failures: (1) systemic inflammation, (2) insulin resistance, and (3) mitochondrial dysfunction/ATP shortage. He argues GH analogs are the foundation of longevity because IGF-1 simultaneously addresses all three. Cancer, cardiovascular disease, neurodegenerative disease, and metabolic disease are all downstream of these three failures.

IGF-1 promotes oligodendrocyte differentiation — these are the cells that produce myelin, the insulation coating nerve axons. This has particular relevance for multiple sclerosis (MS), where myelin degradation is the core pathology. Dr. Bachmeyer mentions treating MS patients in his practice.

The cancer-GH myth originates from animal models where mice were given supraphysiological doses of growth hormone (200+ times greater than normal), which predictably caused tumors. Dr. Bachmeyer argues this is basic toxicology, not relevant pharmacology. Therapeutic doses that restore IGF-1 to youthful levels (~age 22) show cancer risk actually lower than baseline.

IGF-1 increases insulin sensitivity in muscle tissue by upregulating GLUT4 glucose transporter expression. It promotes lipolysis by activating hormone-sensitive lipase in adipose tissue, mobilizing stored fatty acids. By reducing fat mass, it directly addresses the root cause of insulin resistance (adipose tissue releasing inflammatory cytokines and free fatty acids).

IGF-1 (produced downstream of GH analog use) upregulates IL-10 production (anti-inflammatory cytokine) while simultaneously downregulating TNF-alpha and IL-6 signaling. The primary anti-inflammatory mechanism is through strengthening gut barrier tight junction proteins (ZO-1/Zonula Occludens-1 and Occludin), reducing LPS endotoxemia from leaky gut.

Stacking CJC-1295 (GHRH agonist / accelerator) with Ipamorelin (ghrelin receptor agonist / brake release) produces synergistic GH release by using two complementary mechanisms simultaneously. One pushes the accelerator while the other releases the brake, making a significant difference in outcomes.

CJC-1295 is a GHRH agonist that binds to GHRH receptors on somatotrope cells in the anterior pituitary, triggering growth hormone release. Natural GHRH has a half-life of about 7 minutes and degrades almost immediately; CJC-1295 extends this action. It works as the 'accelerator' in the GH system.

Tesamorelin has much greater receptor affinity for the GHRH receptor than CJC-1295, binding more tightly to GHR receptors. This means lower doses and less frequent dosing are needed to achieve the same biological response. Dr. Bachmeyer uses the analogy of knocking on a door that opens immediately (tesamorelin) vs one that takes 10-15 seconds (CJC-1295).

Dr. Bachmeyer states sermorelin is 'crap/garbage' and while CJC-1295 is acceptable, tesamorelin is 'much more effective especially for visceral fat.' He considers tesamorelin the superior GHRH analog choice when combined with retatrutide for body composition optimization.

The speaker warns that blended CJC-1295 and Ipamorelin vials require extremely careful and meticulous reconstitution technique. Improper reconstitution can result in the peptides forming an unusable gel. This is presented as a practical safety and usability concern rather than a pharmacological risk, and is based on the speaker's personal experience.

The speaker reports from personal experience that CJC-1295 and Ipamorelin have significant stability problems when blended together in a single vial. Improper reconstitution of the blend can result in an unusable gel-like substance. Separate vials of each peptide are recommended to avoid this stability issue, despite the added cost and additional injections required.